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A.  Specific Aims of Proposed Research 
 This research proposal investigates the potential prophylactic nature of cinnamon against 
urinary tract infection (UTI) in premenopausal women who suffer from recurrent infection.  The 
purpose of this study is to determine the potential effectiveness of cinnamon intake in reducing 
the risk of UTI in this population through a double-blind, placebo-controlled randomized clinical 
trial (RCT) by comparing the effectiveness of interventions.  The hypothesis states that if 
premenopausal women who suffer from recurrent UTIs ingest 36 mg PAC-standardized ground 
cinnamon product then they will experience a reduced risk of UTI as compared to those 
ingesting a placebo.   
 
B.  Background and Significance 
I.  Motivation for Research and Relevance to Public Health 
This research holds great public health significance.  A UTI is a pathogenic invasion of 
the otherwise sterile urinary tract resulting in inflammation and infection.1 Diagnosis reflects the 
signs of clinical symptoms and bacteriuria.1 The National Center for Health Statistics reports that 
UTIs account for about 8.1 million visits to health care providers annually in the United States.2 
UTIs are the second-most common site for infection and, therefore, a critical health concern 
worthy of research.3     
The incidence and prevalence of UTIs is greater in women and has been attributed to 
female anatomy, hormones, and behavior.1 UTIs are about 50 times more common in adult 
women than men.4 In the U.S. alone, over 11 million women report ever having a UTI per year.5  
The Foxman et al. survey show that the overall lifetime risk of developing a UTI is greater than 
50% for adult women.6 The annual incidence of acute uncomplicated UTI is 7% for all women 
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with peaks for the age groups of 15-24 and greater than 65 years old.7 Unfortunately, women 
also suffer the greatest from recurrent infection.  Recurrent UTI involves experiencing an 
average of two to three episodes a year.8 Among women, up to 25% will experience recurrent 
infection within six months.9 UTIs are considered a chronic health concern because they are 
often persistent and recur.4 After the second recurrence, 30% of these women will have a third 
occurrence, and 80% of this group will have subsequent recurrences.10 High recurrences indicate 
the benefit of a long-term antimicrobial prophylaxis, but rising antimicrobial resistance indicates 
the need for alternatives.11,12   
Infections of the lower urinary tract are common among women due to the female 
anatomical structure.1 The length of the urethra is shorter in women, which allows for bacteria’s 
easier ascent.  The location of the urethral opening is also near potential bacterial sources, 
including the anus and vagina.10 Studies have researched the activity of Escherichia coli (E. 
coli), responsible for nearly 95% of UTIs, to determine its ability to cause UTI.13 Its ability to 
adhere to uroepithelial cells is one factor of its infective potential.14 This bacterial attachment 
induces the body’s immune response and the following cascade of interleukin secretions and 
leukocyte infiltration, which causes inflammation and the ensuing UTI.15   
The administration of antibiotics is the standard treatment prescribed for UTIs.16 This, 
however, is becoming an increasing health concern both biologically and financially.  
Biologically, the possibility of antibiotic resistance rises as recurrent infections and prescriptions 
increase.  Antibiotic therapy has led to bacterial resistance, evidenced by the increase of clinical 
failure rates.5 Financially, UTIs account for over $1.6 billion in direct costs.17 Exploring natural 
prevention, therefore, is both biologically and financially desirable.   
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II.  Summary of Existing Research and Knowledge   
E. coli adheres to cell surfaces by producing two types of adhesins.5 In the case of UTI, 
the E coli’s hair-like fimbria extensions produce adhesins, which attach themselves to receptors 
on uroepithelial cells.18 Cranberry consumption has been associated with UTI prevention for 
nearly 100 years.19 Clinical research finds that a daily dosage of 250 mL of cranberry juice 
prevents UTI recurrence about 50% of the time and reduces bacteria and pyuria.20   
Research has identified proanthocyanidin (PAC) as a primary chemical compound of 
cranberry that prevents bacterial adhesion.5 PACs are biological compounds in plants found to 
protect them from harmful microbe invasions and benefit human health.21 They are defined 
chemically based on their structures as oligomers and polymers of monomeric flavanoids linked 
through specific, or B-type, and double, or A-type, linkage bonds.21 Cranberries contain these 
PACs with A-type linkages.22 Research finds these A-type cranberry PACs to prevent the 
adhesion of uropathogenic E. coli bacteria to uroepithelial cells by inhibiting its P-fimbriated 
adhesion in both ex vivo and in vivo studies.23 Without adhesion, these E. coli cells cannot breech 
the mucosal surface to infect the urinary tract.24 PACs with A-type linkages stop the adherence 
of uropathogenic bacteria to the uroepithelium by inhibiting its P-fimbriated adhesion and 
thereby stop infection before it can occur.25  
The A-type linkage appears to be the important structural feature for bacterial anti-
adhesive activity.5 The study by Howell et al. investigated the anti-adhesive properties of PACs 
by comparing the anti-adhesion activity of cranberry juice, containing A-type PACs, with those 
of non-cranberry products such as apple juice and dark chocolate, which contain B-type PACs.  
The results show that only the consumption of cranberry juice prevented bacterial adhesion.25 If 
the anti-adhesive property was due solely to the presence of fructose or any type of PAC, 
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regardless of type, then all products should have prevented adhesion.  The other food products 
with type-B linkages, however, did not provide the same benefit as the cranberry product with 
type-A linkages.  The current theory supports that it is the presence of PACs containing A-type 
linkages, specifically, which provides anti-adhesive properties and thus prevents UTI.26  
The results of one meta-analysis on intervention studies investigating cranberry intake 
and the prevention of UTI show that cranberry products significantly reduce the number of UTIs 
at 12 months compared to placebo controls and were especially effective in reducing incident 
UTI cases in women with recurrent UTIs.4 While cranberry consumption is effective, the study 
notes that high withdrawal rates suggest it is an unacceptable therapy that cannot be sustained for 
certain populations.4,26 The low palatability and high sugar content of cranberry juice are cited as 
causes for withdrawal.  The cost of consuming large amounts of sugary, marketed juice products 
for the preventative benefit may be too great or undesirable for some people.  Ocean Spray, a 
popular brand of cranberry juice, costs an additional 140 calories and 36 grams of sugar per eight 
ounces and around $6 per 64-ounce bottle.27 In an American population that already over 
consumes calories and sugar, an alternative source of prevention is desirable.  Thus, finding an 
alternative source of a dietary inhibitor of bacterial adhesion, which is both more cost and health 
effective, would provide the benefit of UTI prevention without requiring antibiotics or 
compromising other areas of life.         
This proposed study seeks to further investigate this hypothesized active compound by 
testing the effectiveness of cinnamon, another food product containing PACs with A-type 
linkages, as a prophylaxis against UTI.  The concentration of PACs in cranberry is measured at 
418.8 ± 75.3 mg/100 g and ground cinnamon at 8108.2 ± 424 mg/100 g.22 Costing only 6 
calories per teaspoon and about $2 per 3-ounce jar, cinnamon is a low calorie and price 
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alternative compared to cranberry juice.28 Cinnamon provides a potent dose of PACs with A-type 
linkages and is therefore a potentially powerful prophylaxis. 
 
C.  Research Design and Methods 
I.  Study Design 
This proposed study has been designed to research the relationship between cinnamon, 
adult premenopausal women, and UTI.  A double-blind, placebo-controlled RCT will test 
various interventions for their effectiveness in reducing recurrent UTIs in the study population 
during a 2-year trial period.  Both the participant and outcome assessor will be blind to the 
participant’s assigned intervention group.  The 2012 Review suggests studying the long-term 
benefits in future research since most previous studies concluded after only 12 months.  
Therefore, the 2-year period has been chosen to test the effectiveness over a longer term.   
II.  Exposure and Outcome Definition 
 The primary outcome is defined as the occurrence of a clinically diagnosed UTI during 
the 2-year trial period.  The gold standard for the diagnosis of a UTI is pathogenic detection in 
the urine with the presence of symptoms.29 The threshold bacterial criteria of 100,000 cfu/mL, 
the gold standard, will be used to diagnose culture-confirmed UTI.24 Using the study by 
Stapleton et al. as a model, symptoms include dysuria, frequency, urgency, suprapubic pain, 
hematuria, and pyuria with a blood cell count of at least 10/µL.30 UTI will be defined as cases 
showing bacteriuria with the onset of urinary symptoms including dysuria plus at least one of the 
following symptoms: frequency, urgency, suprapubic pain, hematuria, and pyuria.30 As a 
secondary outcome, women with a urinalysis showing at least 100,000 cfu/mL of bacteria 
without symptoms will be diagnosed as having asymptomatic bacteriuria.  Outcomes will be 
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evaluated every two weeks by assessing for symptoms and collecting urine samples from the 
participants.   
 This study compares the effectiveness of five interventions.  The exposures are defined, 
therefore, according to the type of intervention.  While numerous studies show the effectiveness 
of cranberry, such as consuming 400 mg of cranberry solids or 250 mL of cranberry juice taken 
three times a day, these do not test equivalent dose concentrations of the active compound.31,32 
Products contain various PAC concentrations and processing can impact PAC composition.5  
The specific PAC concentration of a product must be determined, therefore, in a laboratory using 
a technique such as the dimethylaminocinnamaldehyde (DMAC) method.33 Since this study tests 
the effectiveness of PAC as the active compound provided by various sources, the PAC 
concentration of these sources will be standardized.  This ensures equivalent comparisons to test 
the effectiveness of the exposure, PAC presence, to the outcome, UTI occurrence. 
The interventions will be testing the bioactivity of PAC-standardized products containing 
a dosage of 36 mg PAC.  The 2012 Cochrane Review reports that studies show a dosage of at 
least 36 mg of cranberry PAC equivalents/d taken twice daily effectively inhibits bacterial 
adhesion.33 This PAC concentration has been measured, administered, and found to combat UTI 
in two studies using cranberry in both powder and juice forms.24,33 The consistency of results 
though the form differed, suggests the significance of the PAC component at this dose.  
Therefore, this study seeks to further test the effectiveness of the PAC, specifically, regardless of 
its source.   
This proposed study is founded on the hypothesis that foods containing 36 mg PAC, 
provide the anti-adhesive property to protect the uroepithelial cells from infection and thus the 
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body from UTI.  Therefore, this study evaluates the effectiveness of 36 mg PACs by testing 
different sources, both cranberry and cinnamon, to prevent UTI.      
This study will use the DMAC method to quantify and ensure each exposure contains the 
prescribed 36 mg PAC dose, as advised by the 2012 Cochrane Review.24 The five exposures 
include: 1) 1 teaspoon of ground cinnamon added to the diet with a placebo juice and placebo 
tablet, 2) cinnamon tablets containing 400 mg of cinnamon solids with a placebo juice and 
placebo spice, 3) 300 mL cranberry juice with a placebo tablet and placebo spice, 4) cranberry 
tablets containing 400 mg cranberry solids with a placebo juice and placebo spice, and 5) 
placebo tablets, juice, and spice.  The placebos will appear, taste, and smell similar to the test 
products but will not contain any PAC compound.  The hypothesis states that if premenopausal 
women who suffer from recurrent UTIs ingest 36 mg PAC-standardized cinnamon product then 
they will experience a reduced risk of UTI as compared to those ingesting a placebo. 
Each subject will be given two weeks worth of her assigned dosage with directions for 
self-administration.  They will be given recommendations for ways to incorporate the spice into 
their diet, such as adding it to yogurt, toast, or coffee.  She will be responsible for ingesting her 
daily treatment.  She will receive the next supply of treatment each time she reports for data 
collection. 
III.  Study Population and Recruitment 
The participants in this study will be adult, premenopausal women who suffer from 
recurrent UTIs.  Adult, premenopausal women will be defined as females at least 18 years of age 
who have menstrual cycles.  This population is chosen because female hormones are related to 
urinary tract health.  Estrogen, which is more abundant in menstruating women, helps maintain 
the normal acidity of vaginal fluid to promote vaginal flora to protect against UTI.1 There is no 
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maximum age limit so long as menopause has not occurred.  Menopause is defined as having no 
menstrual cycle in the preceding 12 months.34 By selecting on this criterion, this study attempts 
to control the baseline risk factor of hormone level among the study population.   
The definition of recurrent UTI has varied across previous studies from having two to 
four UTIs in the past 12 months to simply having a history of recurrent UTI.4  In this study, it 
will be defined as having at least two diagnosed UTIs in the past 12 months.  This definition is 
based on the natural course of UTI, which generally occurs in episodic clusters, and seeks to 
capture a highly susceptible population.24  
Exclusion criteria includes currently having a UTI, taking an antibiotic within the past 6 
months, having abnormal urinary tract structures, having catherization within the past 12 months, 
pregnancy, or having a cranberry or cinnamon allergy or intolerance.  Women must be screened 
prior to their entry into the study.  Women with urine showing at least 100,000 cfu/mL are 
excluded from the study because they would already meet the threshold for a bacteriuria 
diagnosis, which is one of the outcome measurements.  This screening is critical since women 
may unknowing have this condition.  Regarding retention, they will also be asked and selected 
based on if they plan on maintaining residence in the city for the next two years until the study 
concludes.  The criteria of a 6-month lag time since antibiotic use and 12-month lag time since 
catherization is validated by previous studies.24 Abnormal anatomy of the urinary tract system 
and catherization are factors that greatly increase the risk of UTI.1 Therefore this study will 
select for women with similar risk for UTI by excluding those exposed to these identified risks.  
Pregnant women are excluded from the study because their hormone levels, which are found to 
affect bacterial adhesion, differ in pregnancy.  Lastly, those with a cranberry or cinnamon allergy 
or intolerance are excluded to protect those whose health would be compensated by participating. 
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The study population will be recruited from university medical centers and hospitals in a 
major metropolitan city, such as New York City.  New York is an ideal city because there are 
numerous hospitals and universities within the radius of Manhattan.  It is a densely and diversely 
populated area, which provides for a larger pool from which to recruit.  Additionally, the women 
recruited share a similar urban environment.  A variety of races, ethnicities, lifestyle behaviors, 
and health habits are also represented within an urban population.  The study’s results, therefore, 
can potentially speak to a broader audience and can be stratified on specific factors, such as race 
or behavior.   
Student medical centers at universities are ideal recruitment sites since most females 
seeking health services in this population meet the criteria as adult, premenopausal women.   
Hospitals are also ideal with their variety of medical specialty departments to meet the needs of 
such a densely populated city.  Therefore, hospitals with departments that specialize in women’s 
health can provide for a large study population.  Women will be recruited from general health 
practitioner offices in addition to patients within the urology and gynecology departments.  
Urology, specifically, provides for subjects close to the target population since these women are 
likely seeking help related to their urinary tract health.   
Recruitment methods include posting advertisements in local areas, such as on university 
campuses, and mailing advertisements and interest cards to female student mailboxes.  Clinicians 
will also be asked to refer their patients to the study.  Since 12 months are required to have 
passed since prior UTI, recruitment will be conducted for 18 months.  This allows adequate time 
to recruit potential subjects who have a UTI but can recover before the 12-month critical period 
for enrollment.   
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Recruitment of 1,200 women will be planned for this study.  On the basis of previous 
studies from similar populations, this provides for adequate allotment in each intervention group 
for statistical power while accounting for potential dropout.30 The remaining eligible women, 
after screening, will be randomly chosen to create a study population of 1,050 subjects for 
enrollment.  Then 210 women, validated by Stapleton et al. for significance, will be randomly 
assigned to each intervention group.30 
Once the women have been recruited and screened, those eligible will complete and sign 
their informed consent to participate.  The women will also agree not to consume any additional 
cranberry or cinnamon during the study, as this would increase their PAC dosage and exposure.  
Each subject will be given an identification number to be stored for concealment and used in data 
analysis.  Computer-generated randomization will be used to assign these women to one of the 
five intervention groups.  Randomization theoretically eliminates both known and unknown 
confounders.  Refer to Figure 1 in Appendix for a representative flow chart of this study. 
IV.  Data Collection 
A questionnaire will collect information from the participants at baseline before the study 
begins (Figure 3).  This in-depth, self-reported health history of the subject provides for many 
variables (Figure 2), which can later be used to stratify the data to compare the effectiveness for 
subjects.  Information including age, weight, height, residence, race, and ethnicity will be 
reported.  The participants will also be asked to report the number of previous UTIs they have 
experienced throughout life and the corresponding symptoms.  They will also complete their first 
self-reported questionnaire (Figure 4), as described below, which will be completed every two 
weeks for data collection. An initial urinanalysis will be conducted to evaluate their urinary tract 
health and bacteria concentrations at baseline. 
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Each participant will report to the research clinic once every two weeks in order to collect 
her data throughout the study.  This frequency is done to capture fluctuating bacterial counts.  
First, she will be asked to answer a questionnaire that asks about the presence of symptoms since 
her last visit.  She will be asked to report if she has experienced dysuria, frequency, urgency, or 
suprapubic pain.  Second, a “clean catch” urine sample will be collected to test for pyuria, 
hematuria, and bacteriuria.  A sample showing at least 100,000 cfu/mL will classified as a case 
of bacteriuria.  These cases will then be categorized as culture-confirmed UTI if accompanied by 
symptoms or asymptomatic bacteriuria if symptoms are absent (Figure 5).   
A subject’s participation in the study concludes if she is diagnosed with UTI or 
asymptomatic bacteriuria.  She will be informed about possible treatments and referred to 
physicians.  This is implemented for two reasons.  First, since antibiotics are generally 
administered for treatment and participant eligibility excludes those on antibiotics, a subject 
cannot both seek antibiotic treatment and participate in the study.  Second, it would be unethical 
to withhold or deny treatment from these women in any way for research purposes.  PAC content 
appears to play a role in UTI prevention but not treatment.24 While an alternative option would 
be to allow the woman to voluntarily decide to stay in the study, it is unlikely that she will 
recover without treatment.  Additionally, the bacteria from the first incident would likely 
contribute to causing any subsequent cases.  Therefore, this protocol is implemented to protect 
the study’s ethics and outcome measurements. 
Third, she will complete a self-report questionnaire to collect data on behavior patterns.  
She will be asked questions about her sexual activity regarding type and frequency, indicating a) 
0x/week, b) 1-2x/week, or c) ≥3x/week.  Sexual activity is identified as a risk factor of UTI since 
it introduces bacteria near the urinary tract.1 Therefore, the level of sexual activity would be 
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helpful for data analysis.  This information would allow for the results to be stratified according 
to sexual activity to determine the relationship, if any, between sexual activity, intervention type, 
and risk.  She will also be asked questions about her smoking behaviors, alcohol consumption, 
diet, and physical activity.  These are general factors related to one’s overall health.  This data 
can also be used to stratify and analyze the results, should unforeseen trends arise.  She will also 
report her number of missed doses.  Adherence to the dosing regimen can be calculated by 
dividing the ingested number by the expected number of dosages per two weeks.30 Weighted 
means can be calculated to account for potential missed dosage treatments, if this occurs.30 
Lastly, though she agreed not to ingest either cinnamon or cranberry during the study, this may 
be difficult and ingestion may occur.  Therefore she will be asked to report any such instances.  
The weighted means and self-reports record and account for unanticipated changes in dosage 
exposure.  They can be used to create compliance groups, for example, if necessary in the data 
analysis stages. 
Fourth, in the interest of its subjects, this study is concerned with adverse effects.  They 
will be asked to report gastrointestinal symptoms, often induced by cranberry consumption.30 
Therefore, these can be tracked.  To address this issue, women will be informed of their freedom 
to voluntarily leave the study at any point for any reason at the time of enrollment. 
V. Proposed Analysis Strategy and Main Effect Measures of Interest 
 This study will collect data to determine the following for UTI and asymptomatic 
bacteriuria cases: 1) incidence, 2) incidence density rate, and 3) time to diagnosed case during 
the testing period.   The time to diagnosis is useful to study the longitudinal effectiveness of each 
intervention as a potential prophylaxis.  The incidence, or risk, is defined as the number of cases 
that occur during the 2-year study.  The incidence density rate is the incidence divided by the 
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person-time of the population at risk.  This is useful because participants may voluntarily leave 
and those who develop cases are dropped from the study.  Therefore, the rate reflects that only 
those in the study, still at risk for UTI or asymptomatic bacteruiria, contribute to person-time.  
These risk rates reveal the probabilities of developing UTI and asymptomatic bacteruria in a 
given time period.  The measurements will be calculated to compare and determine if there is a 
reduced risk in any of the interventions.   
Many analysis tables can be created to study the data.  In order to test the hypothesis, a 
2x2 table will be constructed to compare the outcomes from each cinnamon group to the placebo 
group.  In the first table, the data from the “Cinnamon Teaspoon” group will defined as 
“exposed” while the data from the “Placebo” group will be defined as “unexposed” (Figure 6).  
The “disease” corresponds to diagnosed UTI and the “no disease” corresponds to no diagnosed 
UTI.  The results, then, reflect an exposure to 36 mg of PAC delivered through ground 
cinnamon.  From this analysis, the risk ratio (RR) can be determined.  The RR is calculated by 
dividing the risk of disease in the exposed by the risk of disease in the unexposed.  This indicates 
that the risk in the exposed group is “x-times” that of the unexposed.  The equation [RR–1.00 
=x(100%)=x%] can be used to describe the percent increase or decrease in risk with exposure.  
Theoretically, according to the hypothesis, this study predicts a RR less than one and a negative 
“x%” to indicate a decreased risk with cinnamon exposure.  A reduced risk in the cinnamon 
group would support the hypothesis.  A second table and RR can be calculated comparing the 
exposed “Cinnamon Tablet” group to the unexposed “Placebo” group (Figure 7).  These RRs can 
then be compared to determine if cinnamon in the ground or tablet form is more effective.  This 
strategy can also be applied to study asymptomatic bacteriuria as the defined “disease” in later 
analyses.  Additional tables and RRs can likewise be created to compare across intervention and 
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placebo groups, depending on the “exposed” and “disease” definitions and combinations, to 
compare the effectiveness of the exposures as a prophylaxis (Figure 8).   
 Further data manipulation will allow for thorough analysis of the results.  First, the 
women will be collapsed into categories based on age to determine biological significance and 
reveal any trends.  This turns the continuous variable of age into a categorical variable of age 
group.  Three categories of women will be created: 18-28, 29-39, and 40+ years old.  Age may 
be implicated as hormone and immune activity change and studies report UTI peaking in age 
groups.1,7 Second, the women will be collapsed into categories based on the averages of their 
sexual activity.  This creates the following three categories of women according to the mean 
frequency of their sexual activity: 0x/week, 1-2x/week, ≥3x/week.  The biological significance 
of these groups is informed by the studies that show sexual activity as a risk factor.  Likewise, 
stratifying on variables collected in the self-reported health history, such as demographic and 
lifestyle information, can analyze women with certain characteristics.  The effectiveness of the 
interventions according to race, smoking behavior, or any factor can then be compared. 
VI.  Potential Biases, Implications, and Points to Consider 
There are potential biases in this study.  First, the defined diagnosis of UTI is arbitrarily 
set.  While the 2012 Review cites 100,000 cfu/mL as the gold standard, the minimum level of 
bacteriuria reflecting UTI has not been formally defined in scientific literature or standardized by 
microbiological laboratories.29 Diagnosis can vary from 103 cfu/mL to 105 cfu/mL across 
hospitals, labs, and studies.  Each threshold number risks missing relevant case infections.29 
Setting a diagnosis threshold unavoidably introduces the potential to miss infections, which 
could be identified as cases had the criteria been defined otherwise.  The incidence and incidence 
density rate, therefore, may be lower if it misses those below the threshold or higher if it includes 
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more than another threshold.  For purposes of testing, however, the outcome is defined to capture 
the gold standard most commonly used.  UTI is also a broad term and can manifest itself in 
various cases.10 Stapleton acknowledges the inconsistency across previous studies in the 
definition of UTI as the primary outcome.30 This study attempts to address this issue by clearly 
defining its definition of diagnosis based on the gold standard.  The results, therefore, should not 
be used to suggest the effectiveness against all types of UTIs within all populations. 
Second, selection bias is possible.  The women who volunteer and enroll to participate 
may represent a certain population and therefore bias the results.  Since participation requires a 
time commitment and ability to transport oneself to the research clinic twice a month, not all 
women may be able to commit and enroll.  For example, only those women from a higher 
socioeconomic status may be able to afford the time and cost of travel to participate.  One way to 
address and reduce this bias is by making participation more convenient by holding multiple 
locations for data collection.   
Lastly, there is considerable information bias introduced every time a subject reports 
information for data collection.  This includes the questionnaires used to record past UTIs, 
experiences of symptoms, and lifestyle behavior.  These rely on recall accuracy, which also 
unavoidably limits this study.  Their report of symptoms is especially biased since these are 
subjective and may easily be influenced by their participation in this type of study, which is 
focused on UTI.  To address this, the subjects will attend a brief orientation at the time of 
screening which will describe the symptoms.  This will help standardize the way the subjects 
assess and identify the presence of symptoms.  A blind clinician will also be present during 
reporting to help determine a more accurate clinical diagnosis by answering questions to help 
participants assess their symptoms.   
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Appendix 
 
Figure 1: Flow chart of study design and subject counts 
 
Figure 2: Raw data collected from questionnaire 
Variable Variable Type 
Age Continuous 
Height Continuous 
Weight Continuous 
Residence Categorical 
Race Categorical 
Ethnicity Categorical 
# of previous UTIs Categorical 
Sexual activity Categorical 
Physical activity Categorical 
Smoking behavior Categorical 
Alcohol consumption Categorical 
Enrollment 
(1,050) 
Screening and 
Random Selection 
Recruitment 
(1,200) 
Cinnamon Tsp. 
(210) 
Cinnamon Tablet 
(210) 
Cranberry Juice 
(210) 
Cranberry Tablet 
(210) 
Placebo 
(210) 
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Figure 3: Example of possible questionnaire for baseline data collection prior to start of study 
Subject Questionnaire: Baseline 
Name: _________________________ Date: __________ 
Age:  _____ 
Weight: _____ 
Height: _____ 
Zip Code: _____ 
 
Race: Please indicate by checking the appropriate box below 
□ African/African-American 
□ Asian/Asian-American 
□ Caucasian 
□ Hispanic/Hispanic-American 
□ Other: __________________ 
 
Ethnicity: Please indicate by checking the appropriate box below 
□ African 
□ African-American 
□ Asian 
□ Asian-American 
□ Caucasian 
□  Hispanic 
□ Hispanic-American 
□ Other: __________________ 
 
Number of previous lifetime UTI(s) experienced: Please indicate by checking the appropriate 
box below 
□ 2-3 
□ 4-5 
□ ≥ 6 
 
Symptoms experienced: Please indicate all that apply by checking the appropriate box(es) below 
□ Dysuria 
□ Frequency 
□ Urgency 
□ Suprapubic pain 
□ Culture-confirmed pyuria 
□ Culture-confirmed hematuria  
□ Culture-confirmed bacteriuria 
 
BELOW THIS LINE TO BE COMPLETED BY LAB 
 
Bacteriuria content: ________________ 
Hematuria content: ________________ 
Pyuria content: ________________ 
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Figure 4: Example of possible questionnaire for data collection conducted and recorded every 
two weeks throughout study 
Subject Questionnaire: # _____ of 49 
Name: _________________________ Date: __________ 
Smoking behavior: Please indicate by checking the appropriate box below 
□ Never 
□ Smoked previously but have since stopped 
□ Currently smoking 1 cigarette/day 
□ Currently smoking 2-4 cigarettes/day 
□ Currently smoking ≥ 5 cigarettes/day 
Alcohol consumption: Please indicate by checking the appropriate box below 
□ Never    
□ Consume 1 drink/week 
□ Consume 2-4 drinks/week 
□ Consume ≥ 5 drinks/week 
Physical activity: Please indicate by checking the appropriate box below 
□ 0 min/day 
□ ≤ 30 min/day 
□ ≥ 30 min/day 
Physical activity frequency: Please indicate by checking the appropriate box below 
□ 0 days/week 
□ 1 day/week 
□ 2-3 days/week 
□ ≥ 3 days/week 
Sexual frequency: Please indicate by checking the appropriate box below  
□ 0 times/week 
□ 1-2 times/week 
□ ≥ 3 times/week 
Symptoms experienced: Please indicate all that apply by checking the appropriate box(es) below 
□ Dysuria 
□ Frequency 
□ Urgency 
□ Suprapubic pain 
□ None 
Number of sexual partners: Please indicate by checking the appropriate box below  
□ 0  
□ 1 
□ ≥ 2  
Number of doses missed: Please indicate by checking the appropriate box below  
□ 0  
□ 1 
□ ≥ 2  
BELOW THIS LINE TO BE COMPLETED BY LAB 
 
Bacteriuria content:________           Hematuria content:________          Pyuria content:________  
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Figure 5: Diagnosis 
 
 
 
Figure 6 
 
 
Figure 7 
	  
	  
Figure 8: Each exposure and outcome is categorized.  Different combinations can be used to 
construct various additional 2x2 tables. 
Exposed Unexposed Disease No Disease 
Cinnamon Teaspoon Placebo Diagnosed UTI No Diagnosed UTI 
 
Cinnamon Tablet 
 Diagnosed 
Asymptomatic 
Bacteruria 
No Diagnosed 
Asymptomatic Bacteruria 
Cranberry Juice    
Cranberry Tablet    
 
Clean-catch 
sample 
<100,000 cfu/mL  
No diagnosis 
≥100,000 cfu/mL 
No symptoms 
Diagnosed 
Asymptomatic 
bacteruria 
Symptoms 
Diagnosed UTI 
 Cinnamon Teaspoon 
(Exposed) 
Placebo 
(Unexposed) 
Diagnosed UTI (Disease)   
No Diagnosed UTI (No Disease)   
 Cinnamon Tablet 
(Exposed) 
Placebo 
(Unexposed) 
Diagnosed UTI (Disease)   
No Diagnosed UTI (No Disease)   
